- Home
- DAWN
as 02-21-2025 4:00pm EST
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
Upcoming Earnings Alert:
Get ready for potential market movements as Day One Biopharmaceuticals Inc. DAWN prepares to release earnings report on 25 Feb 2025.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 1.2B | IPO Year: | 2021 |
| Target Price: | $36.17 | AVG Volume (30 days): | 782.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.13 - $18.07 | Next Earning Date: | 02-25-2025 |
| Revenue: | $101,953,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 35.37% |
Stock Insider Trading Activity of Day One Biopharmaceuticals Inc. (DAWN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Blackman Samuel C. | DAWN | HEAD OF R&D | Dec 10 '24 | Sell | $13.31 | 30,000 | $399,339.00 | 1,034,015 |
Latest Day One Biopharmaceuticals Inc. News
DAWN Breaking Stock News: Dive into DAWN Ticker-Specific Updates for Smart Investing
Zacks
9 days ago
Does Day One Biopharmaceuticals (DAWN) Have the Potential to Rally 193.16% as Wall Street Analysts Expect?
Zacks
9 days ago
New Strong Buy Stocks for February 13th
GlobeNewswire
11 days ago
Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025
CNN Business
25 days ago
Trump pledged to bring down food prices on Day One. Instead, eggs are getting more expensive
Insider Monkey
a month ago
Why Is Andreas Halvorsen Bullish On Day One Biopharmaceuticals, Inc. (DAWN) Now?
Barrons.com
a month ago
New Tariffs Didn’t Come on Trump’s Day One. A Trade War May Not Be in the Wings.
FastCompany
a month ago
President Trump outlines a frenzy of Day One executive orders and actions: Here’s a list of what to expect
GlobeNewswire
a month ago
Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate Priorities
Compare DAWN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DAWN Day One Biopharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.